These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 33519929)

  • 1. Pharmacological Neuroenhancement: Current Aspects of Categorization, Epidemiology, Pharmacology, Drug Development, Ethics, and Future Perspectives.
    Daubner J; Arshaad MI; Henseler C; Hescheler J; Ehninger D; Broich K; Rawashdeh O; Papazoglou A; Weiergräber M
    Neural Plast; 2021; 2021():8823383. PubMed ID: 33519929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroenhancement and mood enhancement – Physiological and pharmacodynamical background.
    Weiergräber M; Ehninger D; Broich K
    Med Monatsschr Pharm; 2017 Apr; 40(4):154-64. PubMed ID: 29952165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological neuroenhancement and the ability to recover from stress - a representative cross-sectional survey among the German population.
    Bagusat C; Kunzler A; Schlecht J; Franke AG; Chmitorz A; Lieb K
    Subst Abuse Treat Prev Policy; 2018 Oct; 13(1):37. PubMed ID: 30348181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological cognitive enhancement from a perspective of misuse and addiction].
    Franke AG; Soyka M
    Fortschr Neurol Psychiatr; 2015 Feb; 83(2):83-90. PubMed ID: 25723772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine.
    Repantis D; Bovy L; Ohla K; Kühn S; Dresler M
    Psychopharmacology (Berl); 2021 Feb; 238(2):441-451. PubMed ID: 33201262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological neuroenhancement and brain doping : Chances and risks].
    Franke AG; Lieb K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Aug; 53(8):853-9. PubMed ID: 20700786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neuroenhancement in healthy subject? A French case study].
    Micoulaud-Franchi JA; Vion-Dury J; Lancon C
    Therapie; 2012; 67(3):213-21. PubMed ID: 22874487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroenhancement: status quo and perspectives.
    Normann C; Berger M
    Eur Arch Psychiatry Clin Neurosci; 2008 Nov; 258 Suppl 5():110-4. PubMed ID: 18985306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What users think about the differences between caffeine and illicit/prescription stimulants for cognitive enhancement.
    Franke AG; Lieb K; Hildt E
    PLoS One; 2012; 7(6):e40047. PubMed ID: 22768218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Options, limits and ethics of pharmacological neuroenhancement].
    Normann C; Boldt J; Maio G; Berger M
    Nervenarzt; 2010 Jan; 81(1):66-74. PubMed ID: 19851745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement.
    Gahr M; Connemann BJ; Schönfeldt-Lecuona C; Zeiss R
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28067776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of and motives for pharmacological neuroenhancement in Switzerland--results from a national Internet panel.
    Maier LJ; Haug S; Schaub MP
    Addiction; 2016 Feb; 111(2):280-95. PubMed ID: 26189457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review.
    Repantis D; Schlattmann P; Laisney O; Heuser I
    Pharmacol Res; 2010 Sep; 62(3):187-206. PubMed ID: 20416377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Case of Pharmacological Neuroenhancement: Medical, Judicial and Ethical Aspects from a German Perspective.
    Franke AG; Northoff R; Hildt E
    Pharmacopsychiatry; 2015 Nov; 48(7):256-64. PubMed ID: 26252723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Doping for the brain].
    Iglseder B
    Z Gerontol Geriatr; 2018 Feb; 51(2):143-148. PubMed ID: 29209802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of stress, self-efficacy, and self-medication for pharmacological neuroenhancement among employees and students.
    Maier LJ; Haug S; Schaub MP
    Drug Alcohol Depend; 2015 Nov; 156():221-227. PubMed ID: 26455555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals.
    Schifano F; Catalani V; Sharif S; Napoletano F; Corkery JM; Arillotta D; Fergus S; Vento A; Guirguis A
    Drugs; 2022 Apr; 82(6):633-647. PubMed ID: 35366192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. To dope or not to dope: neuroenhancement with prescription drugs and drugs of abuse among Swiss university students.
    Maier LJ; Liechti ME; Herzig F; Schaub MP
    PLoS One; 2013; 8(11):e77967. PubMed ID: 24236008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroenhancement: State of the Art and Future Perspectives.
    Marazziti D; Avella MT; Ivaldi T; Palermo S; Massa L; Vecchia AD; Basile L; Mucci F
    Clin Neuropsychiatry; 2021 Jun; 18(3):137-169. PubMed ID: 34909030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive enhancers versus addictive psychostimulants: The good and bad side of dopamine on prefrontal cortical circuits.
    Bisagno V; González B; Urbano FJ
    Pharmacol Res; 2016 Jul; 109():108-18. PubMed ID: 26826399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.